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Abstract
Nuclear medicine images can help in the diagnosis and assessment of some salivary dis-
orders. 99mTcO4−, gallium-67-citrate scintigraphy will be an indication of the function 
of salivary gland together and it will be used for the diffuse diseases such as sialad-
enitis, Sjögren’s syndrome, sarcoidosis, glossopharyngeal paralysis, and irradiation. It is 
also effective for distinguishing benign tumor legion with Warthin’s tumor and others. 
Moreover, fluorodeoxyglucose positron emission tomography (FDG-PET) is an indis-
pensable modality for determining the localization, focal lesions, and staging of many 
malignant tumors, the fluorodeoxyglucose (FDG) accumulation is visually and semi-
quantitatively assessed using the standardized uptake value (SUV), which is the ratio 
of uptake to the injected dose per unit body weight. Also for radioactive iodine therapy, 
attention should be paid to adverse reactions. It is important to note that acute/chronic 
salivary gland disorders are associated with radioiodine therapy for the treatment of 
postoperative thyroid cancer. Coordination among healthcare providers including 
nurses, radiological technologists, and doctors of all departments involved in treatment 
is important for achieving effective outcomes.
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1. Introduction
Radionuclide imaging, commonly used for the diagnosis of salivary gland diseases, consists 
of salivary scintigraphy using 99mTcO4−, gallium-67-citrate (67Ga) scintigraphy in inflam-
mation, and fluorodeoxyglucose positron emission tomography (FDG-PET). It is important to 
note that acute/chronic salivary gland disorders are associated with radioiodine therapy for 
the treatment of postoperative thyroid cancer.
© 2017 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Salivary gland scintigraphy
2.1. Mechanism of uptake
Salivary glands secrete saliva. The parotid, submandibular, and sublingual glands are called 
the “major salivary glands.” Salivary epithelial cells have a sodium/iodide symporter (NIS), 
which takes up univalent anions such as Cl− and I− and concentrates them (Figure 1). The 
concentrated anion is secreted into saliva. Administered 99mTcO4− (Figure 2) is taken up by 
the salivary glands through NIS, similar to Cl−. Thus, intravenously administered 99mTcO4− 
accumulates mainly in the parotid and submandibular glands and is excreted into saliva [1]. 
After the accumulation of the radionuclide, loading of citric acid, such as lemon juice, stim-
ulates the secretion of saliva, which indicates salivary gland function. Salivary gland scin-
tigraphy is useful for differentiating salivary gland tumors because Warthin’s tumors and 
oncocytomas, which are benign, retain 99mTcO4−.
2.2. Testing procedure
Because salivary gland function is affected by food intake, 1 hour of fasting is needed before 
testing.
Figure 1. Iodide uptake mechanism of sodium/iodide symporter. Sodium/iodide symporter transports two sodium ions 
and one iodide ion into the cytoplasm together.
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For the kinetic analysis of salivary gland function, 185–370 MBq (5–10 mCi) of 99mTcO4− is 
intravenously administered. A dynamic scan (anteroposterior view) is performed at 5-minute 
intervals for 30 minutes. The thyroid gland should be included in the area. Citric acid (e.g., 
lemon juice) is instilled into the oral cavity 20 minutes after the intravenous injection to stimu-
late the secretion of saliva. The regions of interest are set at the bilateral parotid and subman-
dibular glands, and at background regions to generate time-activity curves (TAC). The TAC is 
used to determine the function of individual salivary gland. For the diagnosis of tumors and 
morphology of salivary glands, the intravenously administered dose is 370–740 MBq, and the 
anteroposterior and lateral images are obtained 10–15 minutes after intravenous administra-
tion (Figure 3). When the assessment of the tumor is difficult due to the physiologic uptake in 
the normal salivary glands, washout by stimulating the secretion of saliva is useful.
2.3. Imaging evaluation
2.3.1. Normal images
Salivary gland scintigraphy provides information about the morphology and function of the 
salivary glands and the procedure is easier than that of sialography.
2.3.2. Dynamic scans and TAC
The uptake in the bilateral parotid and submandibular glands begins less than 1 minute after 
intravenous administration of the radionuclide and increases over time. The uptake in the 
parotid glands is equal to or greater than that in the submandibular glands. The sublingual 
glands are not visible, though the reason is unknown. After the stimulation of saliva secretion, 
the uptake rapidly declines in all four glands and subsequently rises again. The percentage 
Figure 2. Structural formula of 99mTcO4−. 99mTcO4− is incorporated into the salivary glands through NIS, similar to 
Cl−.
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of washout is calculated using the counts at the maximum uptake and those at the minimum 
uptake seen after the stimulation of saliva secretion in each gland. The washout (%) is 50% or 
higher in the normal salivary gland (Figure 4).
2.3.3. Static images
The radionuclide uptake of the parotid and submandibular glands are equal to or lower than 
that of the normal thyroid gland, and mild uptake appears in the nasal and oral cavities. On 
the lateral view, the parotid gland is clearly shown, but the submandibular gland overlaps 
with the contralateral submandibular gland.
2.4. Diagnosis of salivary gland tumors
Warthin’s tumors and oncocytomas are derived from the epithelial cells of excretory ducts 
and do not communicate via excretory ducts (Figure 5). Thus, 99mTcO4− is taken up by the 
Figure 3. Static images in normal case. The radionuclide uptake of the parotid and submandibular glands is equal to or 
lower than that of the normal thyroid gland.
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solid component of these tumors and is not eliminated after the stimulation of saliva secretion. 
However, the uptake may be reduced in Warthin’s tumor mainly with a cystic component. 
The diagnostic accuracy of salivary gland scintigraphy for Warthin’s tumors and oncocyto-
mas is around 90%, but these cannot be differentiated in salivary gland scintigraphy. Because 
Warthin’s tumors develop bilaterally in 5–20% of cases, the contralateral parotid gland should 
be carefully evaluated. Meanwhile, because 99mTcO4− is not taken up by pleomorphic adeno-
mas or parotid gland cancer (defect images), salivary gland scintigraphy is useful for differ-
entiation [2].
2.5. Kinetic analysis of salivary gland function
The indications for kinetic analysis of salivary gland function include Sjögren’s syndrome, 
acute/chronic sialadenitis, and facial/glossopharyngeal nerve palsy. Salivary gland func-
tion is assessed based on dynamic images and TAC. In general, chronic sialadenitis shows a 
decreased uptake while acute sialadenitis shows an increased uptake; acute/chronic sialadeni-
tis shows a reduced or no response to stimulation of saliva secretion. Uptake in salivary glands 
is barely evident in patients with severe Sjögren’s syndrome (Figures 6 and 7). The severity 
of the reduction in washout after the stimulation of saliva secretion well correlates with the 
results of the Saxon test. Thus, kinetic analysis reflects the severity of Sjögren’s syndrome, 
allowing an objective assessment of salivary gland function [3].
Figure 4. TAC of the normal salivary gland. After intravenous administration of the radionuclide, uptake in the parotid 
and submandibular glands increases over time. At 20 minutes after administration, saliva secretion is stimulated. Counts 
in the salivary glands rapidly decline and then gradually increase again.
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Figure 6. Sjögren’s syndrome. All four salivary glands show decreased uptake.
Figure 5. Warthin’s tumor. On the image 20 minutes after administration, the radionuclide is taken up by the right 
parotid gland. After the stimulation of saliva secretion, the radionuclide remains in the right parotid tumor. The 
diagnosis was Warthin’s tumor.
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3. Scintigraphy of inflammation (67Ga scintigraphy)
3.1. Mechanism of uptake
67Ga administered intravenously binds to transferrin, a serum protein, and is transported 
into cells through transferrin receptors. The carbon atom of citrate stabilizes the bond 
between 67Ga and transferrin. Transferrin receptors that bind to 67Ga distributed in lyso-
somes and cytoplasm are often present in tumor and inflammatory cells, which show intense 
uptake of 67Ga.
3.2. Testing procedure and imaging evaluation
67Ga is intravenously administered at a dose of 185–555 MBq. Imaging is performed 48–72 
hours after intravenous administration to visualize the distribution of the radionuclide. 
67Ga is excreted from the kidney and intestinal tract within 24 hours after administration 
and is mainly excreted by the liver. Intense uptake of 67Ga is noted in the liver, bone, and 
spleen 48–72 hours after  administration. 67Ga is known to be taken up by inflammation and 
tumors; however, the  sensitivity of 67Ga scintigraphy is low for malignant tumors, while 
the negative predictive value is high. Thus, a negative finding of focal uptake is likely to 
represent a benign lesion or low-grade tumor. Focal uptake in the parotid gland on 67Ga 
scintigraphy is useful for the supplemental diagnosis of Warthin’s tumor. Meanwhile, with 
increased diffuse bilateral uptake, differential diagnosis includes sarcoidosis (Figure 8), 
Figure 7. TAC of the Sjögren’s syndrome. All four salivary glands show decreased uptake and a poor response to 
stimulation of saliva secretion 20 minutes after administration. TAC is useful for assessment.
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IgG4-related disease, Sjögren’s syndrome, and Mikulicz disease. In recent years, 67Ga scin-
tigraphy for tumor diagnosis has been increasingly replaced by  FDG-PET, as described 
below.
4. PET
4.1. Mechanism of uptake
FDG-PET is a critical modality for determining the localization, focal lesions, and staging 
of many malignant tumors, as well as for their follow-up observation. It is also essential for 
the clinical management of salivary tumors [4–8]. Like glucose, fluorodeoxyglucose (FDG) 
Figure 8. 67Ga scintigraphy. Upper column, normal image; lower column, sarcoidosis. Uptake is noted in the bilateral 
parotid glands (arrow), and mediastinal/hilar lymph nodes (arrowhead).
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is taken up by cells via glucose transporters and phosphorylated; however, unlike glucose, 
FDG remains in cells after phosphorylation. In general, glucose transporters and glucose 
metabolism are increased in tumor cells, leading to an increased uptake of FDG (Figure 9). 
The widespread use of PET combined with computed tomography (PET/CT) has increased 
the diagnostic accuracy by compensating for PET disadvantages, including poor spatial reso-
lution and lack of anatomic information. Moreover, PET combined with magnetic resonance 
imaging (PET/MRI) has recently emerged.
4.2. Testing procedure
Fasting is required for 4 hours before testing and intake of liquids with sugar content is pro-
hibited. FDG (Figure 10) is intravenously administered at a dose of 185–444 MBq (5–12 mCi). 
Imaging is performed 60–90 minutes after administration to visualize distribution. The accu-
mulation is visually and semi-quantitatively assessed using the standardized uptake value 
(SUV), which is the ratio of uptake to the injected dose per unit body weight.
Figure 9. Mechanism of FDG uptake. Like glucose, FDG is taken up by cells via glucose transporters and phosphorylated; 
however, unlike glucose, FDG remains in cells after phosphorylation.
Figure 10. The chemical structure of FDG. The chemical structure of FDG is identical to that of 18F (one of the hydroxy 
groups of glucose that is replaced by a positron-emitting radionuclide).




In the head and neck areas, many structures show physiologic uptake, including salivary 
glands, nasal and sinonasal mucosa, extraocular muscles, and lymphoid tissue. Because arti-
facts due to dentures are also often seen, information on CT or MRI images is useful [8].
4.4. Diagnosis of salivary gland tumors
Some lesions are difficult to differentiate from normal structures, postoperative changes, and 
inflammatory changes on CT or MRI images alone. However, those lesions can be diagnosed 
through the combined use of FDG-PET [4, 5, 7]. FDG-PET for medical evaluation or staging of 
a malignant tumor may incidentally reveal a salivary gland tumor [7, 9].
The differentiation of benign from malignant parotid tumors is difficult based on the results 
of FDG uptake alone. Moreover, the differentiation of benign from malignant salivary tumors 
is often difficult based on the comparison of the results of SUVmax alone. A malignant tumor 
tends to show more intense FDG uptake than a benign tumor; however, benign tumors, such 
as Warthin’s tumor and pleomorphic adenoma (Figure 11) [10–12], also show high FDG 
Figure 11. Warthin’s tumor. (a). PET MIP image. (b). PET/CT fusion image. (c). T1-weighted MRI image. FDG is strongly 
taken up by the tumor (SUVmax: 9.4) in the right parotid gland. MRI also provides many findings consistent with 
malignancy. Salivary gland scintigraphy is useful for differentiation.
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uptake. Some studies have reported that the differentiation of benign from malignant salivary 
tumors is possible with the use of indices such as dual-time-point (DTP) imaging and tumor 
volume, in addition to SUVmax [4, 5].
The sensitivity of PET/CT is approximately 80% for the detection of preoperative primary 
lesions (Figure 12), but the accuracy for staging may vary. In particular, FDG-PET images 
often show false-positive results for the diagnosis of cervical lymph nodes.
Sialadenitis may show diffuse, increased uptake. However, some cases may show unilateral 
uptake due to the distribution of inflammation and may be difficult to differentiate from a tumor.
FDG-PET, which provides information about systemic metabolism, is very useful for 
detecting primary or recurrent lesions for the determination of treatment strategy in cases 
with highly-malignant tumors requiring aggressive treatment. FDG-PET aids in detection 
of local involvement, regional lymph node metastasis, distant metastasis, and dissemina-
tion for the clinical staging and restaging. It is also useful in the detection of an incidental 
Figure 12. (a). PET MIP image. (b). PET/CT fusion image. (c). T1-weighted MRI using gadolinium-based contrast (GdT1) 
image. Very strong uptake of FDG (SUVmax: 15.8, arrow) is seen in the region corresponding to the left parotid tumor 
on the MRI image. Uptake is seen in the region of the right internal jugular lymph nodes (SUVmax: 10.2, arrow head). 
Parotid cancer or cervical lymph node metastasis is suspected.
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cancer. Therefore, this imaging modality is essential before the initiation of treatment and 
for patient follow-up [4, 5, 13–15].
5. Salivary gland disorders associated with radioiodine therapy
Radioactive iodine (RAI) therapy is the most widely used treatment for differentiated thyroid 
cancer and has a long history. Because NIS is expressed in the salivary glands, 131I is also 
incorporated into the salivary glands. Not only thyroid cancer but also salivary glands are 
irradiated; and thus, acute/chronic sialadenitis may develop.
5.1. Acute salivary gland disorders
Sialadenitis is one of the most common adverse reactions to RAI therapy. Acute-phase sialad-
enitis causes swelling of the major salivary glands and pain (especially while eating) within one 
to a few days after oral administration of 131I. Although sialadenitis ameliorates without treat-
ment, xerostomia may develop during the chronic phase and significantly impair the quality 
of life. Thus, when symptoms develop, sialadenitis should be treated immediately [16, 17]. The 
parotid glands may be affected more often than the submandibular glands. Steroids are more 
effective than nonsteroidal anti-inflammatory drugs. Cooling and frequent rinsing with cold 
water may relieve symptoms. Taste dysfunction is characterized by reduced acuity for salt taste 
and subsequently sweet taste; bitter taste remains unaffected. Taste dysfunction may become 
obvious later (2–4 weeks after 131I administration), rather than immediately after administra-
tion. To prevent an acute-phase disorder, snacks such as lemon candy to stimulate saliva secre-
tion may be helpful because they also promote the excretion of 131I. Apitherapy using honey 
products is reportedly useful for preventing salivary gland disorders. Massage of the salivary 
glands and aroma therapy are also reported to relieve symptoms [18].
5.2. Chronic salivary gland disorders
Xerostomia may develop during the chronic phase, even in patients without acute impair-
ment. Permanent dysfunction is reported to develop more frequently in the submandibular 
glands than in the parotid glands. Salivary gland scintigraphy shows a pattern of obstructive 
dysfunction before revealing parenchymal damage of the salivary gland. Therefore, salivary 
gland function may improve if salivary gland dysfunction can be identified within the period 
showing an obstructive pattern [19]. Salivary gland function should be monitored regularly 
with scintigraphy or other studies [20].
6. Conclusions
Radionuclide imaging of salivary glands has been used not only for functional assessment but 
also for comprehensive diagnosis including morphological information with the advent of 
single-photon emission computed tomography (SPECT)/CT and PET/CT. Although scientific 
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evidence is limited, the advantages of radionuclide scanning should be determined. For RAI 
therapy, attention should be paid to adverse reactions. Coordination among healthcare pro-
viders including nurses, radiological technologists, and doctors of all departments involved 
in treatment is important for achieving effective outcomes.
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